"Our repositioning and focus on immunotherapies was accompanied by positive financials. Preliminary data obtained from the current programmes encourage us in the development of our innovative therapeutic approaches."
Medigene is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections, and is examining the possibility of using AAV libraries to systematically identify suitable vaccine candidates.
Medigene is responsible for the clinical development of Veregen®, for which it obtained approval, and which is used in the treatment of genital warts. The ointment is marketed globally by business partners.